4.0 Review

Buprenorphine Prescribing: To Expand or Not to Expand

期刊

JOURNAL OF PSYCHIATRIC PRACTICE
卷 22, 期 3, 页码 183-192

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PRA.0000000000000154

关键词

buprenorphine; prescription opioids; abuse; diversion; regulation; policy

资金

  1. VA CSRD [I01BX007080]
  2. NIH/NIDA [P50 DA018197]

向作者/读者索取更多资源

As a result of the prescription opioid epidemic in the United States, there has been an increasing need for effective treatment interventions, both pharmacological and nonpharmacological. Buprenorphine has emerged as a critical component of the treatment of opioid use disorder, yet its adoption has not been without some concerns. This article first reviews the pharmacology, clinical use, and US legislative action related to buprenorphine, followed by a discussion of the misuse and diversion of buprenorphine in the United States as well as internationally. We then explore the impact of buprenorphine abuse as well as discussing strategies for its reduction, including changes in policy, prescription and pharmacy monitoring, and continuing medical education for guiding and improving clinical practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据